UE6 - FC5 - #1 - "Hémostase primaire"

The lifespan of platelets in the body, typically lasting about a week.

The average diameter of platelets, which is around 2 to 4 micrometers.

The distribution of platelets in the body, with a significant portion in the blood (70%) while the rest resides in the spleen (30%).

The normal range for platelet count in the blood, typically between 150,000 and 400,000 per microliter.

The initial phase of hemostasis, a rapid process that usually takes only a few seconds to prevent bleeding.

The primary goal of primary hemostasis is to stop bleeding from a wound.

The key players in primary hemostasis, including platelets, von Willebrand factor, and the vascular endothelium.

The difference in speed between layers of blood flowing inside a vessel.

The main role of ADAMTS13 in the breakdown of von Willebrand factor, converting large multimers into smaller forms.

The extended conformation of von Willebrand factor, which is more prone to aggregation and more sensitive to ADAMTS13 breakdown.

The role of von Willebrand factor in primary hemostasis, facilitating the adhesion of platelets to the damaged vessel wall.

The function of fibrinogen in platelet aggregation, creating bridges between platelets to form a strong network.

The effect of aspirin on platelets, inhibiting the COX enzyme and preventing platelet activation.

The most potent activator of platelets, triggering a strong platelet response.

The targets of common antiplatelet medications like Clopidogrel, Prasugrel, and Ticagrelor.

The characteristic clinical symptom of primary hemostasis disorders, resulting in bruising.

The key role of phosphatidylserine and phosphatidylethanolamine in primary hemostasis, creating a negative charge on the platelet surface.

The involvement of dense granules in primary hemostasis, supporting signaling pathways within platelets.

The essential function of von Willebrand factor in primary hemostasis, crucial for platelet adhesion to damaged vessels.

The structure of von Willebrand factor, composed of multimers with varying sizes.

The test employed for exploring primary hemostasis in vitro, using the PFA-100 device.

The test used to assess the coagulation time of blood plasma.

The test used to study the binding of vWF to the platelet Gp1b9 receptor.

The test used to quantify the concentration of von Willebrand factor protein in the blood.

The main cause of type 2 qualitative defects in von Willebrand disease, characterized by the absence of high molecular weight multimers.

The difference between type 2A and 2B defects in von Willebrand disease.

The test used to analyze the ability of platelets to form aggregates after stimulation with specific agents.

The type of curve obtained during platelet aggregation testing when no aggregation occurs.

The test for therapeutic efficacy and compliance used to check if patients take their aspirin or NSAID medications.

The technique used to examine the structure of platelets, including dense and alpha granules.